New Paradigms to Help Decisions in Treatment Choice: Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases

Laura Loy, Gionata Fiorino, Giulia Roda, Mariangela Allocca, Federica Furfaro, Alessandra Zilli, Daniela Gilardi, Simona Radice, Laurent Peyrin-Biroulet, Silvio Danese

Research output: Contribution to journalArticlepeer-review

Abstract

The increasing armamentarium of drugs for inflammatory bowel disease (IBD) requires a direct comparison of different therapeutic options in order to guide physicians in the choice of the most appropriate treatment for their patients. Head-to-head trials, considered the gold standard in comparative research in IBD, allow to compare different therapies in the same population and setting, but also to evaluate different treatment strategies. Despite head-to-head trials including biologics and immunosuppressive therapy in IBD have been performed decades ago, the interest of these direct comparison is growing since the publication of the first randomized controlled trial directly comparing biologic agents with different molecular targets. This review provides an overview of the past and current IBD head-to-head trial, considering their respective strengths and limitations in a real-life setting.

Original languageEnglish
JournalCurrent Drug Targets
DOIs
Publication statusE-pub ahead of print - Dec 11 2020

Fingerprint Dive into the research topics of 'New Paradigms to Help Decisions in Treatment Choice: Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases'. Together they form a unique fingerprint.

Cite this